Sandoz,inc.

Sandoz,inc. Drugs

• Fentanyl Patch
  

  ×

  Fentanyl Patch

  

  ---

  2.1 Initial Dosing

  Fentanyl Transdermal System should be prescribed only by healthcare professionals who are knowledgeable in the use of potent opioids for the management of chronic pain.

  Due to the risk of respiratory depression, Fentanyl Transdermal System is only indicated for use in patients who are already opioid-tolerant. Discontinue or taper all other extended-release opioids when beginning Fentanyl Transdermal System therapy. As Fentanyl Transdermal System is only for use in opioid-tolerant patients, do not begin any patient on Fentanyl Transdermal System as the first opioid.

  Patients considered opioid-tolerant are those who are taking at least 60 mg of morphine daily, or at least 30 mg of oral oxycodone daily, or at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer.

  Initiate the dosing regimen for each patient individually, taking into account the patient's prior analgesic treatment experience and risk factors for addiction, abuse, and misuse [see Warnings and Precautions (5.1)]. Monitor patients closely for respiratory depression, especially within the first 24–72 hours of initiating therapy with Fentanyl Transdermal System when serum concentrations from the initial patch will peak [see Warnings and Precautions (5.2)].

  The recommended starting dose when converting from other opioids to Fentanyl Transdermal System is intended to minimize the potential for overdosing patients with the first dose.

  Discontinue all other around-the-clock opioid drugs when Fentanyl Transdermal System therapy is initiated.

  While there are useful tables of opioid equivalents readily available, there is substantial inter-patient variability in the relative potency of different opioid drugs and products. As such, it is preferable to underestimate a patient's 24-hour fentanyl requirements and provide rescue medication (e.g., immediate-release opioid) than to overestimate the 24-hour fentanyl requirements which could result in adverse reactions. In a Fentanyl Transdermal System clinical trial, patients were converted from their prior opioid to Fentanyl Transdermal System using Table 1 as a guide for the initial Fentanyl Transdermal System dose.

  Consider the following when using the information in Table 1:

  This is not a table of equianalgesic doses. The conversion doses in this table are only for the conversion from one of the listed oral or parenteral opioid analgesics to Fentanyl Transdermal System. The table cannot be used to convert from Fentanyl Transdermal System to another opioid. Doing so will result in an overestimation of the dose of the new opioid and may result in fatal overdose.

  To convert patients from oral or parenteral opioids to Fentanyl Transdermal System, use Table 1. Do not use Table 1 to convert from Fentanyl Transdermal System to other therapies because this conversion to Fentanyl Transdermal System is conservative and will overestimate the dose of the new agent.

  Table 1*: DOSE CONVERSION TO FENTANYL TRANSDERMAL SYSTEM Current Analgesic Daily Dosage (mg/day) Alternatively, for adult and pediatric patients taking opioids or doses not listed in Table 1, use the conversion methodology outlined above with Table 2. * Table 1 should not be used to convert from Fentanyl Transdermal System to other therapies because this conversion to Fentanyl Transdermal System is conservative. Use of Table 1 for conversion to other analgesic therapies can overestimate the dose of the new agent. Overdosage of the new analgesic agent is possible [see Dosage and Administration (2.3)]. Oral morphine 60–134 135–224 225–314 315–404 Intramuscular or Intravenous morphine 10–22 23–37 38–52 53–67 Oral oxycodone 30–67 67.5–112 112.5–157 157.5–202 Oral codeine 150–447 Oral hydromorphone 8–17 17.1–28 28.1–39 39.1–51 Intravenous hydromorphone 1.5–3.4 3.5–5.6 5.7–7.9 8–10 Intramuscular meperidine 75–165 166–278 279–390 391–503 Oral methadone 20–44 45–74 75–104 105–134 ⇓ ⇓ ⇓ ⇓ Recommended Fentanyl Transdermal System Dose 25 mcg/hour 50 mcg/hour 75 mcg/hour 100 mcg/hour

  Alternatively, for adult and pediatric patients taking opioids or doses not listed in Table 1, use the following methodology:

  1. Calculate the previous 24-hour analgesic requirement. 2. Convert this amount to the equianalgesic oral morphine dose using a reliable reference.

  Refer to Table 2 for the range of 24-hour oral morphine doses that are recommended for conversion to each Fentanyl Transdermal System dose. Use this table to find the calculated 24-hour morphine dose and the corresponding Fentanyl Transdermal System dose. Initiate Fentanyl Transdermal System treatment using the recommended dose and titrate patients upwards (no more frequently than 3 days after the initial dose and every 6 days thereafter) until analgesic efficacy is attained.

  3. Do not use Table 2 to convert from Fentanyl Transdermal System to other therapies because this conversion to Fentanyl Transdermal System is conservative and will overestimate the dose of the new agent. Table 2*: RECOMMENDED INITIAL FENTANYL TRANSDERMAL SYSTEM DOSE BASED UPON DAILY ORAL MORPHINE DOSE Oral 24-hourMorphine(mg/day) Fentanyl Transdermal SystemDose(mcg/hour) NOTE: In clinical trials, these ranges of daily oral morphine doses were used as a basis for conversion to Fentanyl Transdermal System. * Table 2 should not be used to convert from Fentanyl Transdermal System to other therapies because this conversion to Fentanyl Transdermal System is conservative. Use of Table 2 for conversion to other analgesic therapies can overestimate the dose of the new agent. Overdosage of the new analgesic agent is possible [see Dosage and Administration (2.5)]. 60–134 25 135–224 50 225–314 75 315–404 100 405–494 125 495–584 150 585–674 175 675–764 200 765–854 225 855–944 250 945–1034 275 1035–1124 300

  For delivery rates in excess of 100 mcg/hour, multiple systems may be used.

  Hepatic Impairment

  Avoid the use of Fentanyl Transdermal System in patients with severe hepatic impairment. In patients with mild to moderate hepatic impairment, start with one half of the usual dosage of Fentanyl Transdermal System. Closely monitor for signs of sedation and respiratory depression, including at each dosage increase [see Warnings and Precautions (5.14), Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)].

  Renal Impairment

  Avoid the use of Fentanyl Transdermal System in patients with severe renal impairment. In patients with mild to moderate renal impairment, start with one half of the usual dosage of Fentanyl Transdermal System. Closely monitor for signs of sedation and respiratory depression, including at each dosage increase [see Warnings and Precautions (5.15), Use in Specific Populations (8.7) and Clinical Pharmacology (12.3)].

  2.2 Titration and Maintenance of Therapy

  Individually titrate Fentanyl Transdermal System to a dose that provides adequate analgesia and minimizes adverse reactions. Continually reevaluate patients receiving Fentanyl Transdermal System to assess the maintenance of pain control and the relative incidence of adverse reactions, as well as monitoring for the development of addiction, abuse, or misuse. Frequent communication is important among the prescriber, other members of the healthcare team, the patient, and the caregiver/family during periods of changing analgesic requirements, including initial titration. During chronic therapy, periodically reassess the continued need for opioid analgesics.

  The dosing interval for Fentanyl Transdermal System is 72 hours. Do not increase the Fentanyl Transdermal System dose for the first time until at least 3 days after the initial application. Titrate the dose based on the daily dose of supplemental opioid analgesics required by the patient on the second or third day of the initial application.

  It may take up to 6 days for fentanyl levels to reach equilibrium on a new dose [see Clinical Pharmacology (12.3)]. Therefore, evaluate patients for further titration after no less than two 3-day applications before any further increase in dosage is made.

  Base dosage increments on the daily dosage of supplementary opioids, using the ratio of 45 mg/24 hours of oral morphine to a 12 mcg/hour increase in Fentanyl Transdermal System dose.

  If unacceptable opioid-related adverse reactions are observed, the subsequent doses may be reduced. Adjust the dose to obtain an appropriate balance between management of pain and opioid-related adverse reactions.

  A small proportion of adult patients may not achieve adequate analgesia using a 72-hour dosing interval and may require systems to be applied at 48 hours rather than at 72 hours, only if adequate pain control cannot be achieved using a 72-hour regimen. An increase in the Fentanyl Transdermal System dose should be evaluated before changing dosing intervals in order to maintain patients on a 72-hour regimen.

  Dosing intervals less than every 72 hours were not studied in children and adolescents and are not recommended.

  2.3 Administration of Fentanyl Transdermal System

  Fentanyl transdermal system patches are for transdermal use, only.

  Proper handling of Fentanyl Transdermal System is necessary in order to prevent serious adverse outcomes, including death, associated with accidental secondary exposure to Fentanyl Transdermal System [see Warnings and Precautions (5.3)].

  Application and Handling Instructions

  Patients should apply Fentanyl Transdermal System to intact, non-irritated, and non-irradiated skin on a flat surface such as the chest, back, flank, or upper arm. In young children and persons with cognitive impairment, adhesion should be monitored and the upper back is the preferred location to minimize the potential of inappropriate patch removal. Hair at the application site may be clipped (not shaved) prior to system application. If the site of Fentanyl Transdermal System application must be cleansed prior to application of the patch, do so with clear water. Do not use soaps, oils, lotions, alcohol, or any other agents that might irritate the skin or alter its characteristics. Allow the skin to dry completely prior to patch application. Patients should apply Fentanyl Transdermal System immediately upon removal from the sealed package. The patch must not be altered (e.g., cut) in any way prior to application. Fentanyl Transdermal System should not be used if the pouch seal is broken or if the patch is cut or damaged. The transdermal system is pressed firmly in place with the palm of the hand for 30 seconds, making sure the contact is complete, especially around the edges. Each Fentanyl Transdermal System patch may be worn continuously for 72 hours. The next patch is applied to a different skin site after removal of the previous transdermal system. If problems with adhesion of the Fentanyl Transdermal System patch occur, the edges of the patch may be taped with first aid tape. If problems with adhesion persist, the patch may be overlayed with a transparent adhesive film dressing. If the patch falls off before 72 hours, dispose of it by folding in half and flushing down the toilet. A new patch may be applied to a different skin site. Patients (or caregivers who apply Fentanyl Transdermal System) should wash their hands immediately with soap and water after applying Fentanyl Transdermal System. Contact with unwashed or unclothed application sites can result in secondary exposure to Fentanyl Transdermal System and should be avoided. Examples of accidental exposure include transfer of a Fentanyl Transdermal System patch from an adult's body to a child while hugging, sharing the same bed as the patient, accidental sitting on a patch and possible accidental exposure of a caregiver's skin to the medication in the patch while applying or removing the patch. Instruct patients, family members, and caregivers to keep patches in a secure location out of the reach of children and of others for whom Fentanyl Transdermal System was not prescribed.

  Avoidance of Heat

  Instruct patients to avoid exposing the Fentanyl Transdermal System application site and surrounding area to direct external heat sources, such as heating pads or electric blankets, heat or tanning lamps, sunbathing, hot baths, saunas, hot tubs, and heated water beds, while wearing the system [see Warnings and Precautions (5. 11)].

  2.4 Disposal Instructions

  Failure to properly dispose of Fentanyl Transdermal System has resulted in accidental exposures and deaths [see Warnings and Precautions (5.3)].

  Patients should dispose of used patches immediately upon removal by folding the adhesive side of the patch to itself, then flushing down the toilet.

  Unused patches should be removed from their pouches, the protective liners removed, the patches folded so that the adhesive side of the patch adheres to itself, and immediately flushed down the toilet.

  Patients should dispose of any patches remaining from a prescription as soon as they are no longer needed.

  2.5 Discontinuation of Fentanyl Transdermal System

  Significant amounts of fentanyl continue to be absorbed from the skin for 24 hours or more after the patch is removed [see Clinical Pharmacology (12.3)].

  To convert patients to another opioid, remove Fentanyl Transdermal System and titrate the dose of the new analgesic based upon the patient's report of pain until adequate analgesia has been attained. Upon system removal, 17 hours or more are required for a 50% decrease in serum fentanyl concentrations. Withdrawal symptoms are possible in some patients after conversion or dose adjustment [see Warnings and Precautions (5.17)].

  Do not use Tables 1 and 2 to convert from Fentanyl Transdermal System to other therapies to avoid overestimating the dose of the new agent resulting in overdose of the new analgesic and possibly death.

  When discontinuing Fentanyl Transdermal System and not converting to another opioid, use a gradual downward titration, such as halving the dose every 6 days, in order to reduce the possibility of withdrawal symptoms [see Warnings and Precautions (5.17)]. It is not known at what dose level Fentanyl Transdermal System may be discontinued without producing the signs and symptoms of opioid withdrawal.

  Close
  More Info